相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy
Gian Paolo Fadini et al.
ACTA DIABETOLOGICA (2020)
Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials
Edoardo Mannucci et al.
DIABETES OBESITY & METABOLISM (2020)
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETES CARE (2020)
Older Adults: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies
Mario Luca Morieri et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2020)
Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients
Mario Luca Morieri et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting
Luigi F. Meneghini et al.
DIABETES OBESITY & METABOLISM (2019)
Deintensification in older patients with type 2 diabetes: A systematic review of approaches, rates and outcomes
Samuel Seidu et al.
DIABETES OBESITY & METABOLISM (2019)
Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study
Mario Luca Morieri et al.
DIABETES OBESITY & METABOLISM (2019)
HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs
Andreas Fritsche et al.
BMJ OPEN DIABETES RESEARCH & CARE (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study
Hermione Price et al.
DIABETES OBESITY & METABOLISM (2018)
A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients
Mirna S. Abd El Aziz et al.
DIABETES OBESITY & METABOLISM (2017)
Glucagon-like peptide- I receptor agonists: a systematic review of comparative effectiveness research
Philip A. Levin et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2017)
Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China
Linong Ji et al.
DIABETES OBESITY & METABOLISM (2017)
Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials
Sylvie Erpeldinger et al.
BMC ENDOCRINE DISORDERS (2016)
Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
Julio Rosenstock et al.
DIABETES CARE (2014)
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
Michaela Diamant et al.
DIABETES CARE (2014)
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)
C. Mathieu et al.
DIABETES OBESITY & METABOLISM (2014)
分享论文
